Skip to search formSkip to main contentSkip to account menu

CEP-701

Known as: CEP 701, CEP701 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

lestaurtinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Increase in the functional capacity and quality of life among stroke patients by family caregiver empowerment program based on adaptation model
2015
2015
BINARY PROPERTIES FROM CEPHEID RADIAL VELOCITIES (CRaV)
We have examined high accuracy radial velocities of Cepheids to determine the binary frequency. The data are largely from the… 
Highly Cited
2009
Highly Cited
2009
IMAGING AND MODELING RAPIDLY ROTATING STARS: α CEPHEI AND α OPHIUCHI
We present submilliarcsecond resolution imaging and modeling of two nearby rapid rotators α Cephei and α Ophiuchi, obtained with… 
Highly Cited
2007
Highly Cited
2007
Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.
In the prostate, cellular growth and differentiation are finely regulated by a complex interaction between stromal and epithelial… 
2007
2007
D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia
MLL rearranged and hyperdiploid acute lymphoblastic leukemia (ALL) are characterized by high-level FLT3 expression and… 
Highly Cited
2006
Highly Cited
2006
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.
The receptor tyrosine kinase FLT3 is a promising molecular therapeutic target in acute myeloid leukemia (AML). Activating… 
Highly Cited
2006
Highly Cited
2006
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
We have developed a useful surrogate assay for monitoring the efficacy of FLT3 inhibition in patients treated with oral FLT3… 
Highly Cited
2005
Highly Cited
2005
A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations…
Background: Activating mutations of FLT3 occur in roughly 30% of adults with AML and are associated with an increased relapse… 
Highly Cited
2004
Highly Cited
2004
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.
Internal tandem duplication mutations of the FLT3 gene (FLT3/ITD mutations) are the most frequent molecular abnormality in acute… 
1999
1999
The Novel Trk Receptor Tyrosine Kinase Inhibitor CEP‐701 (KT‐5555) Exhibits Antitumor Efficacy against Human Pancreatic Carcinoma (Panc1) Xenograft Growth and In Vivo Invasiveness
Abstract: The survival rate for patients with pancreatic ductal adenocarcinoma (PDAC) is among the poorest for all cancers. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)